MarketPulse

PALISADE-3 trial

10 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

VTGN Investors Face March 16 Deadline in Securities Fraud Class Action

Securities class action filed against VTGN alleges misleading statements about fasedienol drug and PALISADE-3 trial. Investors must act by March 16, 2026 deadline.
VTGNPhase 3 clinical trialsecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Vistagen Hit with Securities Fraud Lawsuit Over Fasedienol Trial Data

Class action lawsuit filed against $VTGN alleges securities fraud over misleading statements about fasedienol drug candidate and PALISADE-3 clinical trial data.
VTGNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Investors Face March 16 Deadline in Securities Lawsuit Over Trial Disclosures

Rosen Law Firm urges Vistagen investors to join securities class action by March 16, 2026, over alleged misstatements regarding fasedienol and clinical trials.
VTGNsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Vistagen Faces Class Action Over Alleged Misstatements on Fasedienol Trial Data

Class action lawsuit filed against $VTGN alleging securities fraud over fasedienol drug trial statements and concealed adverse clinical data.
VTGNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Securities Lawsuit: Investors Face March 16 Deadline in PALISADE-3 Trial Dispute

Vistagen faces securities fraud lawsuit over fasedienol trial misstatements. Affected investors have until March 16, 2026 deadline to seek lead plaintiff status or secure counsel.
VTGNPhase 3 clinical trialsecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Faces Securities Lawsuit Over Fasedienol Drug Claims

Vistagen Therapeutics faces securities lawsuit over alleged fasedienol misstatements. Investors who purchased VTGN stock April 2024-December 2025 may be eligible for compensation; lead plaintiff deadline is March 16, 2026.
VTGNPhase 3 clinical trialsecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Investors Face March Deadline in Securities Litigation Over Trial Disclosures

Vistagen faces securities lawsuit over misleading trial disclosures. Investors must nominate lead plaintiff by March 16, 2026 deadline.
VTGNsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Lawsuit Filed Against Vistagen Over Alleged Misstatements on Drug Trial

Class action lawsuit filed against Vistagen Therapeutics for alleged false statements regarding drug trial data. Investors who purchased securities April 2024-December 2025 may be eligible.
VTGNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Investors Face March Deadline in Securities Litigation Over Trial Disclosures

Vistagen investors face March 16, 2026 deadline in securities lawsuit alleging false statements about drug trials and clinical data that misled shareholders.
VTGNsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Securities Litigation: Investors Face March Deadline to Join Class Action

Vistagen faces securities class action over alleged misleading statements about drug fasedienol. Investors who purchased stock April 2024-December 2025 can join by March 16, 2026 deadline.
VTGNinvestor lossessecurities class action